Institute of Biomedical Research Corp. (MRES)
Podgorica, ME
Institute of Biomedical Research Corp. (MRES) is a dedicated provider of comprehensive biomedical research and analytical services, operating both within Montenegro and across international markets. The company's core activities encompass fundamental scientific investigation and robust research and development initiatives for new biomedical products, advanced technologies, and innovative diagnostic methods, including experimental medical treatments. MRES also focuses on the creation of novel biomedical and food products. A significant part of its mandate involves regulatory oversight of industrial activities and their associated products, alongside scientific environmental monitoring. Furthermore, it delivers expert regulatory evaluation and certification services for a wide array of biomedical products. The institute also contributes to academic advancement through graduate research study programs in the biomedical and environmental fields. MRES manufactures and supplies a diverse range of healthcare devices. Its offerings include two-channel analog NMS units, various digital muscle stimulators, digital TENS devices, interferential therapy units, elite combination models, portable four-channel digital stimulators, and portable ultrasound equipment. The product portfolio also extends to photon red light devices for aesthetic applications, electric pain relief solutions, microcurrent electrical nerve stimulators, and high-volt pulsed stimulators. The company excels in the development and commercialization of specialized agents and products. This category features microbicidal agents, a variety of disinfectant solutions, and specialized medical supplies such as bandages tailored for severe burns. They also provide products for hard surface disinfection, microbicidal treatments for fabrics and textiles, insecticides (including those targeting bed bugs), microbicidal towels, and mouthwash. Key innovations include Purilair, an apparatus specifically designed for sterilizing compressed air within medical instruments, alongside colloidal silver and other electro-medical devices. A notable product is BioStim INF, which is engineered for reducing edema, alleviating pain, and delivering comprehensive therapeutic benefits. Beyond its product and research endeavors, MRES offers a broad spectrum of essential services. These include quality control, regulatory assistance, healthcare support, environmental analysis, building decontamination, and extensive environmental protection and management services. They are also a critical source for regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was established in 2010 and maintains its headquarters in Podgorica, Montenegro, with a representative office located in Montreal, Canada, facilitating its global operations.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +30.77% | +13.33% | -10.53% | -71.67% | -39.29% | -91.50% | -80.00% | +30.77% | -78.75% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+9.8% ★ Q4'25: -100.0% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%-133.3% Q4'25: -100.0% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,494.6%
-
EBIT margin Biotechnology: +0.0%-1,463.5%
-
ROIC Biotechnology: -16.1%-28.7% Q4'25: -9.1% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+12.3% Q4'25: +14.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'24)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Drasko D. Pekovic | Founder, Chairman of the Board, Chief Executive Officer & President | — | — |
| Teodor Burtea | Director & Member of Scientific Council | — | male |
| Victor Lange | Chief Executive Officer of M2MMA | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MRES
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
